Figure 5. Exacerbation of tau pathology in Pdx1^+/−/APP/PS1 mouse brains.

(A) HE staining showing the location of the hippocampal CA3 subfield of the Pdx1^+/−/APP/PS1 mouse brain. Representative immunohistochemical staining for p-Tau (Thr205)- and p-Tau (Ser396)-positive areas in the hippocampal CA3 subfield of WT, Pdx1^+/−, APP/PS1, and Pdx1^+/−/APP/PS1 mice. Scale bar = 60 μm. (B) Representative Western blots of total tau and tau phosphorylated at Ser396, Ser404, Thr205, and Thr231 in the homogenized brain tissues of Pdx1^+/−, APP/PS1, Pdx1^+/−/APP/PS1, and WT littermate mice at 41 weeks of age. GAPDH was used as an internal control. (C–F) Densitometric analyses of the immunoreactivities to the antibodies presented in the previous panel. Data represent the mean ± S.E. (n = 10). *p < 0.05, **p < 0.01 compared with the WT control group; ^#p < 0.05, ^##p < 0.01 compared with the APP/PS1 group.